An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter

This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.

开始日期2025-07-08

申办/合作机构

CorMedix, Inc.

NCT06453876

/ Not yet recruiting临床3期IIT

Percutaneous Embolectomy, Ultrasund Assisted Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

The STRATIFY II trial investigates the efficacy of three different approaches to reducing thrombus burdon in patients with acute intermediate high-risk pulmonary embolism: percutaneous embolectomy (the Flow Triever® system, INARI medical), USAT (EKOS® system, Boston Scientific with low dose alteplase) and heparin with the option to perform full-dose thrombolysis. As a co-primary secondary end point the trial assess the incremental efficacy of the embolectomy vs the catheter based low dose thrombolysis approach.
Thus the two main hypothesis being tested are:
1. Thrombus burden reduction after 48-96 h is increased with a catheter based (embolectomy or USAT) compared to the a heparin with optional high dose thrombolysis approach (1st co-primary outcome)
2. Thrombus burden reduction after 48-96 h is increased with percutaneous embolectomy compared to USAT with low-dose alteplase (2nd co-primary outcome)

开始日期2025-06-01

申办/合作机构

Rigshospitalet

[+2]

NCT06845423

/ Recruiting临床4期IIT

Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk. An Open-label, Randomized, Controlled Trial Comparing Two Strategies With or Without Pharmacological Thromboprophylaxis

Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4/1000 women, half of VTE occurring during postpartum and as PE in majority of cases, accounting for 8.8% of maternal deaths.
Majority of postpartum VTE occurs in women with one or more moderate risk factors (obesity, caesarean section, postpartum hemorrhage). For these women at intermediate risk, the efficacy and safety of thromboprophylaxis have not been assessed yet during postpartum and international guidelines for pharmacological thromboprophylaxis, based on data extrapolated from other populations, observational studies and small clinical trials are inconsistent across countries.
We designed an open-label, randomized, controlled trial, aiming to demonstrate the superiority of a pharmacological thromboprophylaxis strategy with LMWH (LMWH type chosen according to physician / patient's preference) during 6 weeks after delivery (the 6-weeks follow-up visit being matched with usual care) in women at intermediate risk, over no pharmacological thromboprophylaxis.

开始日期2025-05-16

申办/合作机构

University Hospital of Brest

100 项与肝素钙相关的临床结果

登录后查看更多信息

100 项与肝素钙相关的转化医学

登录后查看更多信息

100 项与肝素钙相关的专利（医药）

登录后查看更多信息

57,027

项与肝素钙相关的文献（医药）

2026-01-01·ANNALS OF VASCULAR SURGERY

One-Year Functional Patency and Comparison of Superficialization Techniques for Brachiobasilic Arteriovenous Fistulas

Article

作者: Sandigo-Saballos, Isabela ; Hurwitz, Mikayla ; Valadez, Maria ; Archie, Mark ; Ugarte, Ramsey ; Montero Arcila, Veronica ; de Virgilio, Christian

BACKGROUND:

Superficialization of brachiobasilic arteriovenous fistulae (BBAVFs) is generally performed by either creating a shelf or dividing, tunneling, and transposing the vein with reanastomosis. This multiinstitutional study evaluates the impact of these techniques and other variables on BBAVF functional patency at 12 months.

METHODS:

A retrospective review of patients who underwent two-stage BBAVF between 2014 and 2019 with at least 1-year follow-up was conducted from 5 safety net hospitals. The primary end point was functional patency at 12 months. Bivariate and multivariate logistic regression models evaluated the relationship between preoperative and intraoperative variables and fistula function at 12 months.

RESULTS:

There were 260 patients with an overall 12-month functional patency rate of 71.5%. Use of aspirin (odds ratio [OR] 1.858, 95% confidence interval [CI] 1.023-3.372, P = 0.042) and intraoperative anticoagulation (OR 2.118, 95% CI 1.193-3.760, P = 0.01) at the first stage procedure, and previous arteriovenous fistula or graft (OR 0.465, 95% CI 0.233-0.928, P = 0.030), were associated with functional patency at 12 months. When comparing shelfing versus transposition techniques, there was no significant difference in the functional patency rates (83.6% vs. 89.9%, P = 0.179), although the shelfing technique was associated with a higher rate of postoperative complications (19.8% vs. 9.0%, P = 0.027).

CONCLUSION:

In patients undergoing 2-stage BBAVF, the use of aspirin and intraoperative heparin at the first stage procedure are associated with higher functional patency at 12 months. Functional patency was similar for the shelfing technique versus transposition at the second stage. The shelfing technique was associated with higher rates of postoperative complications, primarily related to wound healing.

2026-01-01·ANNALS OF VASCULAR SURGERY

Safety and Efficacy of Bivalirudin as a Heparin Alternative in Patients Undergoing Carotid Artery Stenting

Article

作者: Maningat, Alexandra L ; Lewis, Anthony J ; Shah, Sahaj ; Guo, Tian ; Elmore, James ; Salzler, Gregory G ; Ryer, Evan J ; Kania, Thomas A

BACKGROUND:

Transfemoral carotid artery stenting (TFCAS) and transcarotid artery revascularization (TCAR) are commonly used to treat carotid stenosis. However, the need for heparin alternatives during these procedures and their impact on outcomes remain unclear. This study evaluates the safety and efficacy of bivalirudin, the most commonly used heparin alternative, compared to heparin.

METHODS:

The Vascular Quality Initiative registry was queried for carotid artery stenting procedures performed from 2010 to 2022. Propensity-matched analyses compared outcomes between patients receiving intraprocedural heparin and those receiving bivalirudin. Primary outcomes were postoperative neurological events, including stroke or transient ischemic attack, and bleeding. Secondary outcomes included 30-day rates of reintervention and myocardial infarction, and mortality at 30 days and 1 year.

RESULTS:

Among 80,172 carotid artery stenting procedures, 2,789 (3.47%) were performed with bivalirudin. In the heparin group, 24,797 (34.1%) underwent TFCAS with distal embolic protection, while 47,961 (65.9%) underwent TCAR with flow reversal. In the bivalirudin group, 2,494 (91.2%) underwent TFCAS, and 240 (8.8%) underwent TCAR. Propensity matching created 2 cohorts of 957 patients each. There were no significant differences in neurological events (odds ratio, [OR]: 1.44, 95% confidence interval [CI]: 0.72-2.86; P = 0.30), bleeding (OR: 1.0, 95% CI: 0.53-1.90; P = 1.00), 30-day mortality (OR: 2.05, 95% CI: 0.62-6.85; P = 0.24), or 1-year mortality (OR: 1.37, 95% CI: 0.84-2.24; P = 0.21).

CONCLUSION:

Bivalirudin is a safe and effective alternative to heparin for patients with contraindications to heparin undergoing carotid artery stenting. These findings suggest no significant differences in outcomes, supporting bivalirudin as a viable anticoagulation option.

2025-12-31·ANNALS OF MEDICINE

Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection

Article

作者: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Huang, Han ; Liu, Silan ; Chen, Min

BACKGROUND:

Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.

METHODS:

A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.

RESULTS:

Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.

CONCLUSION:

Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.

311

项与肝素钙相关的新闻（医药）

2025-07-18

·PRNewswire

B. Braun Expands Heparin Sodium Injection Portfolio to Seven Heparin Premixed Sodium Injection Products

BETHLEHEM, Pa., July 18, 2025 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium Injections into the U.S. market, expanding its portfolio to include 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL). These launches expand B. Braun's portfolio to become the largest offering of Heparin Premixed bags in the U.S. market. The 250 mL and 500 mL bags will feature a 2D enhanced barcode. The 2D enhanced barcode design includes the National Drug Code (NDC) number, lot number and expiration date, along with increased spacing between the two 1D barcodes. These enhancements are designed to help improve the accuracy and efficiency of barcode scanning. The B. Braun Heparin portfolio is manufactured using EXCEL® IV Containers, which are not made with DEHP, PVC or natural rubber latex, prioritizing patient and environmental safety. The product is produced and distributed from B. Braun's Irvine, California pharmaceutical manufacturing facility. "Expanding our Heparin Sodium Injection portfolio underscores our commitment to healthcare providers and their patients. By offering the largest selection of premixed Heparin products in the market, we are helping to provide healthcare workers with the tools they need to deliver precise and effective care," said Shawn Brinson, Director of Marketing, Injectable Drugs, B. Braun Medical Inc. Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL), are indicated as anticoagulants to maintain catheter patency. For additional information, please see full Prescribing Information. IMPORTANT SAFETY INFORMATION Contraindications: History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT) Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) In whom suitable blood coagulation tests — e.g., the whole blood clotting time, partial thromboplastin time, etc., — cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation About B. Braun B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. The company employs 8,500 people at over 30 locations across North America. Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website. SOURCE B. Braun Medical Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-07-17

·赛柏蓝

15个药被重点监控（附名单）

作者 | 颜色编辑 | 郑瑶截至目前，已经累计有15个药品被纳入重点监控名单。 01新增被点名的药有2个7个药已被5次点名7月16日，上海阳光医药采购网发布《关于公布2025年5月药品挂网公开议价采购监管品种名单的通知》，10个药被纳入重点监控（具体名单见文末附件）。赛柏蓝梳理发现，今年发布的1-5月药品挂网公开议价采购监管品种名单中，累计有15个药品被重点监控。5月份新增的监控药品有2个，分别为活血通脉胶囊（0.25g*36 粒/盒，药用铝箔，聚氯乙烯固体药用硬片）、肝素钙注射液。活血通脉胶囊主要用于活血通脉、强心镇痛等，肝素钙注射液则是一种抗凝血药物。上海公布的重点监控品种名单按药品采购金额降序排列，自今年以来，有7个药品已经累计被点名5次，具体如下：上海还公布了原在库超“黄线”品种、新申请超“黄线”品种以及未通过公允性品种各10个。原在库超“黄线”品种按超黄线幅度降序排列，其中泼尼松片、红霉素肠溶片、苯巴比妥片、盐酸多西环素片、盐酸左西替利嗪口服滴剂这5个品种在今年历次名单中均被点名。新申请超“黄线”品种中，注射用天麻素、护肝宁胶囊、消炎利胆胶囊以及川芎茶调丸均被点名过5次。未通过公允性品种按超提示价幅度降序排列，其中“活血止痛膏”属于此次新增被点名的药品。上海指出，公布品种仅作为提醒，需要医疗机构根据市场供需情况以及阳光平台“红黄绿线”议价实时提醒信息合理议价。通常来看，医院需建立药品使用动态评估机制，例如对重点监控品种开展专项处方点评，将合理用药指标纳入绩效考核。上海部分医院对超 “黄线” 品种实施 “双签字” 议价制度，强化采购决策的合规性。02药品价格治理下半场集采、价格监测、支付创新.....上海自2018年起全面实施药品挂网公开议价采购机制，采用“信息推送、绿线参考、黄线提醒、红线拦截”的询价议价模式。医疗机构根据市场供需情况以及阳光平台“红黄绿线”议价实时提醒信息合理议价。药品价格治理已在全国形成规模化实践。截至目前，至少有28个省份已完善药品挂网规则，大批药品通过价格治理回归合理区间。“深化医药价格改革治理，规范医药价格秩序”被明确列为2025年医保工作重点，下半年治理将聚焦集采扩围、价格监测、支付创新、监管强化发力。以第十一批国采为例，7月16日起企业已启动信息填报，截至7月31日17:00审核通过的各厂牌药品信息将作为本次医疗机构填报需求量的选择范围，此次拟纳入的55个品种（含倍他米松注射剂、地氯雷他定口服液体剂等），将通过集中议价进一步优化价格。除国家级集采外，中成药领域的专项集采与地方联盟采购也有望加速推进。集采形成 “国家+地方”的覆盖格局，推动药品价格治理从“单点突破”向“全国联动”升级。与此同时，2025年国家医保目录调整已经开始，下半年将发布第一版商业健康保险创新药品目录，主要纳入超出保基本定位、暂时无法纳入基本目录，但创新程度高、临床价值大、患者获益显著的创新药，在控费与创新之间找到更精准的平衡。监管层面的深化同样值得关注。在国家医保局统一部署下，今年3月中下旬起，应用药品追溯码打击药品领域欺诈骗保和违法违规问题专项行动在全国范围内相继开展。8月起，国家医保局将启动第二阶段专项核查，并针对诱导协助参保人年底“冲顶消费”等违法违规行为，于10-12月开展第三阶段集中攻坚行动。定点零售药店还通过建立 “量价比较指数” 实施动态监测，形成 “事前预警、事中核查、事后整改” 的全链条监管闭环，确保价格治理落地见效。下半年，药品价格治理正在深化。附：END内容沟通：郑瑶（13810174402）

2025-07-14

·CPHI制药在线

业绩亏损，股价却连创新高，这三家药企做对了什么？

关注并星标CPHI制药在线随着今年创新药支持政策的大爆发，以及国内创新药企研发实力不断提升，从2025年初至今，创新药板块不断创出新高。其中常山药业、一品红、舒泰神三家创新药概念股行情火爆，这三家药企既不是创新药龙头，而且过去一年业绩仍处于亏损之中。那么，是什么造就了这些药企"业绩走低、股价上涨"的现象？常山药业先看常山药业，其股价短期爆发力惊人，今年5、6月份，短短2个月时间，股价涨幅近300%，若拉长时间线来看，过去两年已经涨了10倍多，成为当之无愧的十倍股。常山药业前身为1993年成立的河北常山生化制药厂，以肝素粗品生产起步。后经历几次技术改进、扩张，2011年8月，常山药业正式登陆创业板。肝素是一种天然存在于哺乳动物肥大细胞与中性粒细胞的黏多糖类物质，在临床主要用于抗凝血和抗血栓。常山药业是国内少数拥有完整肝素产业链的企业，产品涵盖肝素粗品、肝素原料药和肝素制剂药品。凭借肝素原料药和制剂业务，2016-2022年间，公司累计盈利12.4亿元。2023年，受集采冲击，常山药业业绩遭遇"滑铁卢"。在第八批全国药品集中带量采购中，常山药业的那屈肝素钙注射液虽然中标，但价格降幅较大。此外，公司主力品种低分子量肝素钙未纳入全国性集采，导致销售收入较2022年度下降46.51%。最终，2023年，常山药业迎来上市后首年亏损，营收锐减至14.1亿元，归母净利润巨亏12.4亿元。2024年，常山药业继续亏损2.49亿元。在业绩连续两年亏损的情况下，常山药业靠胰高血糖素样肽-1受体（GLP-1R）激动剂艾本那肽，为资本市场带来了想象空间。艾本那肽是在全球首款上市的GLP-1药物艾塞那肽基础上，采用化学修饰技术，将艾塞那肽与重组人血白蛋白结合形成。艾本那肽作为一种长效GLP-1R激动剂，半衰期可达7天。2024年4月，艾本那肽的糖尿病适应症国内上市申请获受理。今年5月，艾本那肽拟用于减重适应症的临床试验申请已获得国家药监局受理。在艾本那肽的加持下，常山药业成为GLP-1风口上的新星，被资本疯抢。曾有公开数据统计，常山药业从2023年以来，区间最大涨幅超1300%。对此，常山药业多次澄清：艾本那肽申请上市适应症为治疗2型糖尿病，不涉及肥胖适应症。即使未来肥胖适应症获批上市，也将面临激烈的市场竞争，盈利存在较大不确定性。可狂欢中的人们根本无暇顾及这些提醒。一品红一品红成立于2002年，以仿制药起家，2017年在深交所上市，一品红主要聚焦于儿童药、慢病药领域，现有 26 个儿童药注册批件和 66 个慢病药注册批件，产品结构丰富。在创新项目上，公司主要聚焦在代谢、炎症、神经等领域，共有15个创新药项目。由于一品红转型较早，前几年实实在在吃到了集采红利，然而由于去年7月，一品红在第七批国家药品集采盐酸溴己新注射液投标中存在违约情形，不仅被要求退还集采销售所得2.66亿元，还被暂停从2024年8月21日至2025年2月20日参与国家组织药品集中采购的资格。这一惩罚使得一品红元气大伤。业绩方面，2024年，实现营收14.5亿元，同比下降42.07%，净利润为-5.40亿元，上市后首次迎来亏损；2025年一季度营收3.77亿元，同比下降39.48%，净利润为5659万元，同比下降43.7%。但是在营收大幅下滑，净利润首亏背景下，一品红的股价还是从开年时的不足20元涨到6月份的57.31元，主要原因就在于公司的一款痛风创新药：氘泊替诺雷。痛风是一种尿酸过度沉积导致的疾病，据《2021中国高尿酸及痛风趋势白皮书》显示，截至2020年全球高尿酸及痛风患病人数为9.3亿人，中国高尿酸血症的患病人数约为1.77亿，痛风患病人数约为1466万，且新发患者逐渐年轻化。可以说，这一领域市场相当可观。与巨大的临床需求相对应的，是有限的治疗选择。目前国内外指南推荐的一线治疗高尿酸/痛风的药物为别嘌醇和非布司他，但别嘌醇有过敏风险，非布司他被FDA黑框警告心血管风险。痛风市场亟待一个安全性与疗效性俱佳的好药。氘泊替诺雷是一款URAT1抑制剂，基于苯溴马隆改造而来。目前，URAT1抑制剂在痛风创新药研发领域深受追捧，国内外在研产品约37个。除了已经上市的多替诺雷和排队等待的恒瑞同靶点药物外，一品红的氘泊替诺雷等已在国内进入III期临床。并且AR882在已完成的全球多中心IIb期临床试验中，展现出显著的疗效和良好的安全性，有望成为潜在的BIC产品，为痛风患者提供一种更安全、更有效的治疗选择。痛风领域之外，一品红还开发了创新药物APH01727，这是一种高活性、高选择性的GLP-1RA，旨在成为每日一次的口服小分子GLP-1R激动剂，用于2型糖尿病的治疗。舒泰神舒泰神成立于2002年8月，这家老药企在成立初期依靠鼠神经生长因子（商品名：苏肽生）带来业绩。鼠神经生长因子能够促进神经生长和修复，巅峰时期，这款药物销售额超过12亿元。但是最终由于疗效存疑，苏肽生于2019年被移除出医保目录，舒泰神业绩受到重创。好在公司的创新药研发进展还算顺利。其注射用STSP-0601的上市申请已获国家药监局受理，适应症为用于伴抑制物的血友病A或B成人患者出血按需治疗。血友病是一种因体内凝血因子缺乏导致凝血障碍的遗传性出血性疾病，根据国家统计局2024年全国人口数14亿计算，全国存量血友病患者人群大约为14万人。目前该病治疗方式国内主要为定期注射凝血因子产品，但这种治疗方式会产生抑制凝血因子的抗体，导致患者受伤后，还是会发生无法止血的现象。STSP-0601通过激活凝血因子X，促进凝血酶生成，在IIb期研究中，STSP-0601达到了预设的主要有效性终点。6月5日，STSP-0601被国家药监局纳入优先审评品种名单，进入药品上市许可优先审评审批程序；并获得FDA用于治疗A型血友病和B型血友病的孤儿药认定。STSP-0601的出色表现，使得舒泰神在不到一个月时间，股价涨了近5倍，达30多元/股，创近几年新高。纵观以上三家药企，股价飙升除了与医药行业景气度提高有关外，主要在于企业自身抓住风口，给出了想象力。这也进一步体现了公司产品规划的前瞻性。接下来，这些"风口创新药"的审批进展与商业化落地将直接影响股价走向。而公司当前的涨幅和市值，是否与其基本面相匹配，见仁见智。主要参考资料： 1、《起底"神药"艾本那肽》，医曜，2025.06.11. 2、Ribatti D. The failed attribution of the Nobel Prize for Medicine or Physiology to Viktor Hamburger for the discovery of Nerve Growth Factor. Brain Res Bull. 2016;124:306-9. doi: 10.1016/j.brainresbull.2016.02.019. 3、《舒泰神，复刻热景和三生制药，悄然崛起？》，生物星海，2025-05-27.END智药研习社近期直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

带量采购财报医药出海核酸药物申请上市

100 项与肝素钙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04427	肝素钙	S01XA14 B01AB01 C05BA03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
凝血障碍	中国	Sanofi Winthrop Industrie SA	2000-12-07
静脉血栓栓塞	中国	Sanofi Winthrop Industrie SA	2000-12-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性阻塞性肺疾病	临床2期	英国	Ockham Biotech Ltd.	2022-01-30
囊性纤维化	临床1期	英国	Ockham Biotech Ltd.	2022-01-30
1型糖尿病	临床1期	德国	Sanofi	2017-02-17
哮喘	临床前	英国	Ockham Biotech Ltd.	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2025	N/A	慢性血栓栓塞性肺动脉高压 heparin anti-platelet-factor (PF)-4 antibody \| lupus anticoagulant \| cold agglutinins antibodies	1,087	Heparin (Control group of non-PF4+ PTE patients)	選構製鬱餘鑰醖願鑰夢(網糧廠膚夢襯鹽鹹窪遞) = no difference across groups 鑰糧製願壓獵築鬱憲遞 (獵築壓繭襯築蓋齋鏇衊 ) 更多	-	2025-05-16
Inha University Hospital Stroke Prospective Registry (ISC2025)	N/A	血栓形成	460	Heparin during MT	簾範衊網艱鑰醖醖糧製(積範鏇蓋蓋膚憲鬱鑰築) = 範製觸糧範繭觸獵衊憲範遞鹽願艱觸構壓範窪 (齋齋衊糧簾選憲築選糧, 12.5)	不佳	2025-01-30
				No Heparin during MT	簾範衊網艱鑰醖醖糧製(積範鏇蓋蓋膚憲鬱鑰築) = 網範觸糧壓網積襯鏇壓範遞鹽願艱觸構壓範窪 (齋齋衊糧簾選憲築選糧, 10.1)
ESC2024	N/A	葡萄糖代谢紊乱	-	Heparin premedication	積壓餘衊製襯顧壓壓壓(膚糧獵襯憲廠淵範夢簾) = 簾廠製壓夢淵襯獵顧窪蓋簾蓋製遞醖餘衊憲夢 (襯壓鏇憲齋廠壓願鹽憲 )	-	2024-08-30
				No heparin premedication	積壓餘衊製襯顧壓壓壓(膚糧獵襯憲廠淵範夢簾) = 鑰鏇淵遞齋蓋顧鹹鏇鑰蓋簾蓋製遞醖餘衊憲夢 (襯壓鏇憲齋廠壓願鹽憲 )
ATS2024	N/A	血肿	-	Heparin infusion	選艱夢窪糧醖衊遞齋製(衊鹹積餘繭願糧糧糧齋) = SPH in a patient on heparin was first described in 1996, almost 80 years after heparin was first used. The very few reported cases of SPH almost always involve (a diverse, interesting list of) predisposing elements. Combined use of Bronchoscopy and SSDSA can allow for rapid localization and control of hemorrhage from the bronchial or the pulmonary arterial system. Follow-up imaging is usually required to rule out infection, the most feared complication. 醖憲範構鏇繭壓糧築醖 (鹹簾蓋獵網選製壓廠襯 )	-	2024-05-19
NCT02984384 (PREVENT CLOT, CTgov)	临床3期	血栓形成 \| 创伤和损伤	12,424	Low Molecular Weight Heparin (Low Molecular Weight Heparin (LMWH)-Enoxaparin)	構願鹽膚鹹窪艱蓋餘顧 = 簾獵鑰壓遞願鹹蓋顧構齋鹹顧鑰獵艱夢製膚廠 (蓋繭繭鬱蓋廠鹽艱繭網, 廠艱網膚獵窪齋顧醖製 ~ 壓夢構衊簾鹽衊鹹遞鑰) 更多	-	2024-05-14
				Acetylsalicylic acid (Acetylsalicylic Acid (ASA)-Aspirin)	構願鹽膚鹹窪艱蓋餘顧 = 蓋膚獵夢選廠衊壓鹹簾齋鹹顧鑰獵艱夢製膚廠 (蓋繭繭鬱蓋廠鹽艱繭網, 簾餘簾齋餘網鏇網憲夢 ~ 構齋繭鹹蓋願構鏇憲遞) 更多
AAN2024	N/A	肝素诱导的血小板减少伴血栓形成	-	Heparin (Ocular Ischemic Syndrome (OIS))	願顧鬱繭襯衊選廠鏇築(製繭範簾範獵觸膚艱蓋) = OIS is a rare complication of HITT, occurring within two weeks of repeat exposure to heparin following initial exposure within three months. Awareness of both conditions is crucial to guide prompt management and optimal care to prevent neurologic sequelae. 鹹製膚淵觸蓋鹹襯壓鹹 (襯鹹遞壓網糧顧構繭鬱 )	-	2024-04-09
ESC2024	N/A	心源性休克	-	heparin (Normal fibrinogen levels and normal INR)	鏇願餘鹽遞餘蓋顧餘齋(顧繭憲繭選鏇蓋醖鹽鑰) = 憲製淵壓願憲艱艱鑰製蓋遞範觸繭鹹鏇鏇顧鑰 (醖艱膚襯襯範艱築遞觸 )	-	2024-03-09
				heparin (Reduced fibrinogen levels and/or prolonged INR)	鏇願餘鹽遞餘蓋顧餘齋(顧繭憲繭選鏇蓋醖鹽鑰) = 壓餘餘簾糧餘願積觸襯蓋遞範觸繭鹹鏇鏇顧鑰 (醖艱膚襯襯範艱築遞觸 )
PERIOP-01 (ASH2023)	N/A	结直肠癌	614	Extended duration thromboprophylaxis with low-molecular-weight-heparin	憲醖鏇積獵窪壓淵鹽繭(襯觸憲鹽憲願選蓋淵淵) = 構築夢網襯蓋鹽鏇窪壓繭糧繭窪淵範夢窪襯醖 (顧鑰築憲鏇觸壓窪廠觸 ) 更多	-	2023-12-10
				Standard duration thromboprophylaxis	憲醖鏇積獵窪壓淵鹽繭(襯觸憲鹽憲願選蓋淵淵) = 糧艱選衊觸廠鹹網簾醖繭糧繭窪淵範夢窪襯醖 (顧鑰築憲鏇觸壓窪廠觸 ) 更多
ESC2023	N/A	-	768	Heparin dose 50IU/kg	顧襯夢顧夢顧鑰憲遞憲(遞廠夢觸膚積鬱鏇齋鬱) = 築壓鹽簾淵壓壓簾襯鹽願遞餘繭製淵艱憲顧齋 (獵鹹襯夢築壓襯觸襯簾 )	-	2023-08-27
				Heparin dose ≥70IU/kg	顧襯夢顧夢顧鑰憲遞憲(遞廠夢觸膚積鬱鏇齋鬱) = 範糧淵餘築齋窪顧衊壓願遞餘繭製淵艱憲顧齋 (獵鹹襯夢築壓襯觸襯簾 )
ATS2023	N/A	血栓形成	-	Heparin	遞鏇築艱鏇壓襯餘憲鬱(範遞鏇構簾願夢衊憲鹹) = Frequently described complications of HIT thrombosis (HITT) include arterial thromboembolism including acute limb ischemia, myocardial infarction and venous thromboembolism. Stroke is relatively rare and associated with higher mortality and more severe thrombocytopenia. Thrombocytopenia is independently associated with higher mortality in HIT. 窪衊膚鹹遞壓蓋製窪鑰 (選憲獵獵醖築餘蓋糧窪 ) 更多	-	2023-05-21
				Argatroban